Physician profile
Camille Angela Clare
NPI 1851473219
$1,686.72
in general payments reported to CMS, 2019-2025
16 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2021: $125 · 2022: $214 · 2023: $392 · 2024: $431 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $308.91 | 2022-2025 | |
| Lilly USA, LLC | $162.01 | 2025 | Mounjaro |
| Baxter Healthcare | $143.72 | 2024 | Starling System |
| Hologic Sales and Service, LLC | $141.32 | 2024 | Acessa Provu System, Omni Hysteroscope, Novasure |
| Glaxosmithkline, LLC. | $140.52 | 2023 | Shingrix |
| Pfizer INC. | $132.01 | 2023 | |
| Myovant Sciences INC. | $125.00 | 2021 | |
| Progenics Pharmaceuticals, INC. | $121.23 | 2024 | |
| Novo Nordisk INC | $119.80 | 2023 | |
| Viiv Healthcare Company | $64.47 | 2025 | |
| Amag Pharmaceuticals, INC. | $64.07 | 2019 | |
| Gilead Sciences, INC. | $49.11 | 2019 | |
| Neotract INC. | $46.87 | 2019 | |
| Abbvie INC. | $42.84 | 2019 | |
| Organon LLC | $24.84 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Clare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.